Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys

Federico Mingozzi(Spark Therapeutics (United States)), Katherine A. High(Spark Therapeutics (United States)), Xavier M. Anguela(Children's Hospital of Philadelphia), Robert J. Davidson(Children's Hospital of Philadelphia), Liron Elkouby(Children's Hospital of Philadelphia), Mustafa N. Yazicioglu(Children's Hospital of Philadelphia), Christian Hinderer(Children's Hospital of Philadelphia), Alex Tai(Children's Hospital of Philadelphia), Armida Faella(Children's Hospital of Philadelphia), J. Fraser Wright(Oxford BioMedica (United Kingdom)), Etiena Basner‐Tschakarjan(Children's Hospital of Philadelphia), Yifeng Chen(Children's Hospital of Philadelphia), Carolann Howard(Children's Hospital of Philadelphia), Gregory M. Podsakoff(Mundipharma (United Kingdom)), Daniel J. Hui(Children's Hospital of Philadelphia), Shangzhen Zhou(Penn Presbyterian Medical Center), Giulia Pavani(Children's Hospital of Philadelphia)
Science Translational Medicine
July 17, 2013
10.1126/scitranslmed.3005795
Cited by 346

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Gene therapy comes of age
|Science|2018|1.4k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
|The Lancet|2016|464